Producción CyT
Congreso
Autoría
Cura Andrea Cecilia
;
Tribbia Liliana Teresita
;
ECHEVERRIA, FLORENCIA
;
Rela Lorena
;
Taravini Irene Rita Eloisa
Fecha
2022
Editorial y Lugar de Edición
Sociedad Argentina de Investigación en Neurociencias
Resumen
Información suministrada por el agente en
SIGEVA
L-DOPA is the most effective drug for the treatment of Parkinson’s disease (PD); however, long-term administration develops L-DOPA induced dyskinesia (LID). LID is associated with the remodeling of dendritic spines of striatal neurons and with intermittent fluctuations in brain dopamine levels, promoting neurodegeneration or contributing to the establishment of pathological mechanisms mediated by glia. Various approaches have been considered to slow the progression of PD and nutraceutical...
L-DOPA is the most effective drug for the treatment of Parkinson’s disease (PD); however, long-term administration develops L-DOPA induced dyskinesia (LID). LID is associated with the remodeling of dendritic spines of striatal neurons and with intermittent fluctuations in brain dopamine levels, promoting neurodegeneration or contributing to the establishment of pathological mechanisms mediated by glia. Various approaches have been considered to slow the progression of PD and nutraceuticals have received attention. An inverse association between yerba mate (YM) consumption and the risk to develop PD was found. Besides, it was tested that YM favors survival and growth of dopaminergic neurons in culture. To assess whether YM has the potential to reduce LID, we conducted a pilot study in an animal model of PD. C57BL/6 mice received YM for 2 months and then were unilaterally lesioned with 6-hydroxydopamine in the medial forebrain bundle. After one month, they received L-DOPA in dyskinetogenic doses for 14 days and the severity of the dyskinesias was recorded. Our preliminary results show that YM treatment exhibits a discernible trend to reduce LID in comparison to the control. Upcoming experiments will clarify whether longterm YM administration decreases the severity of LID, and whether its therapeutic effectcould correlate with the degree of microglial and astrocytic reactivity, and plastic changes inthe synaptic microarchitecture of striatal neurons.
Ver más
Ver menos
Palabras Clave
YERBA MATEDYSKINESIAPARKINSON'S DISEASE